Remazolam is a new ultra-short-acting benzodiazepine that produces sedation by acting on γ-aminobutyric acid type A(GABAA)receptors.Remazolam has characteristics of rapid onset of action,short half-life,high clearance,and no accumulation in the body.It also has a low incidence of injection pain and mild effects on hepatic and renal function,respiration,and haemodynamics.Additionally,it can be rapidly reversed by flumazenil.The clinical research progress on remazolam in the areas of procedural sedation,induction,and maintenance of general anesthesia were reviewed to provide references for its clinical application.
Result Analysis
Print
Save
E-mail